Abstract

2322322222 322 regeneration.

IPC Classes  ?

• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 31/22 - Organic complexes
• C01C 1/02 - Preparation or separation of ammonia

Abstract

Inter-alia, an implantable lens is disclosed comprising a refractive element causing chromatic aberration and an element inducing an increase of the chromatic aberration. It is further disclosed a method for producing an implantable lens.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• G02C 7/04 - Contact lenses for the eyes

Abstract

The present invention relates to a phosphomimetic RAGE protein comprising an amino acid sequence that is at least 90% identical to a native mammalian RAGE isoform or fragment thereof wherein at least one serine present in the cytoplasmatic tail of the mammalian RAGE isoform is replaced by a phosphomimetic structure. The invention further relates to a polynucleotide encoding phosphomimetic RAGE protein and a vector comprising the polynucleotide. Finally, the invention relates to a composition comprising carrier and an active pharmaceutical ingredient, selected from the RAGE protein the vector for use in the treatment or prevention of a disease in a patient, wherein the disease is preferably selected from a disease initiated by impaired DNA repair, a disease initiated by increased DNA damage or a disease initiated by increased senescence.

IPC Classes  ?

• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

The present invention relates to a binding polypeptide comprising a first variable T cell receptor (TCR) domain and a second variable TCR domain wherein (i) the complementarity determining region 3 (CDR3) of the first variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:1 or a sequence at least 80% identical thereto; and/or wherein the CDR3 of the second variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:2 or a sequence at least 80% identical thereto; or wherein (ii) the CDR3 of the first variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:3 or a sequence at least 80% identical thereto; and/or wherein the CDR3 of the second variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:4 or a sequence at least 80% identical thereto; and to polynucleotides, host cells, methods, uses, kits, and devices related thereto.

IPC Classes  ?

• C07K 14/725 - T-cell receptors

Abstract

The present invention provides method of studying an effect of a test substance on a test sample of bio-logical cells using a set of relevant parameters and a set of meta-features, the method comprising: exposing the test sample to the test substance; determining parameter values of the set of relevant parameters for each of a plurality of cells in the test sample; and determining feature values of the set of meta-features for the test sample, wherein each of the feature values is calculated from the parameter values of a cluster of correlated parameters from the set of relevant parameters that is associated with the respective meta-feature, wherein a reference sample for determining the set of meta-features was exposed to a stimulus substance.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

The present invention relates to cyclic peptide compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein. Preferred scavenger compounds are said cyclic peptides comprising at least two lysines, at least one amino acid with an acidic side chain, at least one Dap and a hydrophobic modification, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the cyclic peptides as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the cyclic peptides for the prevention and/or treatment of a disease caused by or associated with methylglyoxal (MG) and/or reactive carbonyl species (RCS), in particular caused by or associated with elevated MG levels, such as diabetes and its associated complications, cardiovascular diseases and obesity.

IPC Classes  ?

• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
• C07K 7/64 - Cyclic peptides containing only normal peptide links

Abstract

The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium/skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention concerns the field of therapeutic and diagnostic antibodies against SARS-CoV-2. Specifically, the invention relates to an antibody which specifically binds to the receptor binding domain (RBD) of SARS-CoV-2 spike protein with an equilibrium dissociation constant (Kd) of less than 10-9 M. The present invention further relates to a polynucleotide encoding the antibody of the invention, a vector or expression construct comprising said polynucleotide, a host cell comprising said polynucleotide, vector or expression construct, or a non-human transgenic organism comprising the polynucleotide, vector or expression construct of the invention. Yet, the invention relates to a method for producing the antibody of the invention and to the use of the host cell of the invention for producing the antibody of the invention. Moreover, the preset invention provides for using an antibody, a polynucleotide or a vector of the invention for treating and/or preventing a disease or condition or for using the antibody for diagnosing said disease or condition. Finally, the invention relates to a kit for diagnosing SARS-CoV-2 infection in a subject.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a method for identifying an antibody that binds the SARS-CoV-2 spike protein with high affinity, the method comprising the steps of: (a) determining the presence of IGKV1-39 in the light chain and/or IGHV3-9 in the heavy chain of said antibody; and (b) identifying an antibody that binds the SARS-CoV-2 spike protein with high affinity if IGKV1-39 is present in its light chain and/or IGHV3-9 is present in its heavy chain. The present invention also relates to a method for manufacturing an antibody, a method for assessing whether a subject produces antibodies that bind the SARS-CoV-2 spike protein with high affinity, and to uses, kits, antibodies, and polynucleotides related thereto.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The application relates to a sensor data processing module including a plurality of integrated circuit devices each configured to receive and process sensor data, in particular sensor data from a PET scanner, at least some of the integrated circuit devices each comprising: at least one data input for receiving measurement data from at least one sensor; at least one data input for receiving a plurality of sensor events from at least one other integrated circuit device, wherein each sensor event comprises at least a time information and an event information; and at least one data output for sending one or more sensor events; wherein the integrated circuit devices each comprise one or more FIFO buffers for temporarily storing one or more sensor events and the integrated circuit devices are each configured: to create one or more sensor events from the measurement data, wherein each sensor event comprises at least a time information and an event information; and to process the sensor events queued in the one or more FIFO buffers by sorting the sensor events located at the front of the queues at least based on the time information; and wherein at least two of the plurality of integrated circuit devices are connected such that the data output of one integrated circuit device is connected to the data input of at least one other integrated circuit device.

IPC Classes  ?

• H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom
• G01T 1/00 - Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation

Abstract

The invention relates to oral pharmaceutical compositions of an active agent and a lipid conjugate of a cell penetrating peptide conjugated to a lipid molecule. The conjugated lipid acts as a permeation enhancer for the active agent in the composition. In other words, oral bioavailability of the active agent increases when co-administered together with the lipid conjugate described herein.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions

Abstract

The present invention relates to conjugate compounds which comprise a peptide moiety (a) which is preferably a hydrophobic modified preS-derived peptide of hepatitis B virus or a respective cyclic peptide, and a NTCP substrate moiety (b), which is preferably a bile acid. The present invention further relates to pharmaceutical compositions comprising at least one conjugate compound. The present invention further relates to medical uses of said conjugate compounds and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a said diseases and/or infections.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Abstract

Described herein is a method for identifying a subject suffering from a severe form of a metabolic disease, including a) obtaining (i) at least partial nucleic acid sequences of at least two alleles of a gene contributing to the metabolic disease or at least partial amino acid sequences of the polypeptides expressed therefrom; and (ii) a residual activity of the polypeptides expressed from the at least two alleles, and b) based on the result of step a), identifying a subject suffering from a severe form of a metabolic disease. Also described herein are methods, data collections, devices, kit, and computer program products related thereto.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6869 - Methods for sequencing

Abstract

The invention relates to the use of a recombinant porcine adeno-associated virus (AAV) vector comprising a peptide-modified porcine AAV serotype 1 (AAVpol) capsid in gene therapy of muscle and/or central nervous system (CNS) disorders, in particular neuromuscular diseases such as genetic neuromuscular diseases.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to an immune modulator comprising (i) a compound of formula I or a pharmaceutically acceptable salt or solvate thereof: The present invention relates to an immune modulator comprising (i) a compound of formula I or a pharmaceutically acceptable salt or solvate thereof: The present invention relates to an immune modulator comprising (i) a compound of formula I or a pharmaceutically acceptable salt or solvate thereof: wherein X and Y are independently selected from —CH2— and —O—, preferably are —CH2—; Z is N or C, preferably is N; m is an integer of from 0 to 3, preferably is 0; n is an integer of from 1 to 3, preferably is 1; R1 is, optionally substituted, C5-C6 cycloalkyl or aryl: R2 is, optionally substituted, aryl or heteroaryl; R3 and R4 are —H, or R3 and R4 together form a —CH2—CH2— bridge; R5 and R7 are independently selected from alkyl, preferably methyl and isopropyl; and in case Z is N, R6 is absent, or, in case Z is C, R6 together with R5 forms a —CH═CH—CH═CH— bridge; and/or (ii) a C—C chemokine receptor type 5 (CCR5) inhibitor, for use in treating and/or preventing pneumonia, sepsis, and/or coronavirus infection in a subject, and to methods, uses, kits an devices related thereto.

IPC Classes  ?

• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to an effector polypeptide comprising (i) an amino acid sequence at least 70% identical to the amino acid sequence RSNLGWLCLLLLPIPLIVWVKRK (SEQ ID NO: 1); and (ii) an exchange of an amino acid to a non-identical amino acid at least one position selected from the list consisting of positions 1, 2, 3, 19, 22, and 23 of the amino acid sequence of (i). The present invention also relates to a polynucleotide comprising a nucleic acid sequence encoding the aforesaid effector polypeptide, and to related host cells, pharmaceutical compositions, and uses, and to related uses in medicine, in particular in treating and/or preventing cancer, inflammatory disease, or acute or chronic neurodegenerative disease.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 14/715 - Receptors; Cell surface antigens; Cell surface determinants for interferons

Goods & Services

Antibiotics for human use; Antibiotic preparations for human purposes; Anti-septics for human use; Bactericides for human use; Germicides for human use; Microbicides for human use; Antibiotic, antibacterial, antiseptic, bactericide, and germicide preparations for human use with efficacy against multi-resistant bacteria; Antibiotic preparations with chemical modifications including peptide-modifications for human use. Scientific and technological services, research and development relating to antibiotics for human use; Providing scientific, industrial analysis and research services in the field of chemistry, pharmacology and biology relating to antibiotics for human use; Providing scientific and industrial advice in the field of chemistry, pharmacology and biology relating to antibiotics for human use; Scientific and technological services and research relating to improving antibiotics efficacy for overcoming antibiotic resistance for human use; Product development and quality control relating to improving antibiotics efficacy for overcoming antibiotic resistance for human use. Medical and human health care services relating to antibiotics for human use; Providing medical and human health care relating to antibiotics for human use; Medical and human health care consultancy relating to antibiotics for human use; Medical and human health care services relating to improving antibiotics efficacy for overcoming antibiotic resistance for human use; Providing medical analysis services in the field of chemistry, pharmacology and biology relating to antibiotics for human use; Providing medical advice in the field of chemistry, pharmacology and biology relating to antibiotics for human use.

Abstract

The present invention relates to an immunoreactive molecule that specifically recognises and binds to human Ankyrin Repeat Domain-Containing Protein 30A (NY- BR-1) and, in particular, to an immunoreactive molecule, which shows no cross- reactivity to other human Ankyrin repeat domain containing proteins. The invention further relates to the use of such immunoreactive molecules in the treatment of cancer as well as in companion diagnostics methods.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors

Abstract

The present invention relates to a method for preparing a compound T having a thioether group from a compound D having a disulfide group in the presence of a carbene.

IPC Classes  ?

• C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure

Abstract

The disclosure in particular relates to a ventricular assist device for implantation into a lumen of a blood vessel, comprising an impeller fixed to a rotor shaft, wherein the impeller is configured to rotate around a longitudinal axis of the rotor shaft; a drive unit comprising a magnetic motor configured to cause rotation of the impeller around to the longitudinal axis; a first active magnetic bearing configured to bear a first end section of the rotor shaft relative to the drive unit; a second active magnetic bearing configured to bear a second end section of the rotor shaft relative to the drive unit; and a control unit configured to control the magnetic motor, the first active magnetic bearing and the second active magnetic bearing.

IPC Classes  ?

• A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
• A61M 60/237 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller the blood flow through the rotating member having mainly axial components, e.g. axial flow pumps

Abstract

The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP). The present invention relates to a compound of formula (I), a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP).

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61P 35/00 - Antineoplastic agents
• A61K 49/10 - Organic compounds
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The present invention relates to cobicistat and its derivatives or prodrugs for use in the prophylaxis and/or treatment of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, severe acute respiratory syndrome coronavirus (SARS-CoV) infection and/or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. The present invention further relates to methods of prevention and/or treatment of SARS-CoV-2 infection.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/4433 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure provides a computer implemented method for facilitating a teaching surgeon to teach or assist a learning surgeon in minimally invasive interventions using a surgical instrument including displaying endoscopic images of an intervention site in real time on a display device, said endoscopic images being captured using a camera associated with an endoscopic instrument, and tracking a movement of one or both hands of said teaching surgeon and/or a device held by said teaching surgeon, using a real-time tracking apparatus, wherein said real-time tracking apparatus comprises a tracking system and a computing device, wherein said tracking of said movement comprises recording a sequence of tracking information of one or both hands of said teaching surgeon and/or the device held by said teaching surgeon.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G09B 5/02 - Electrically-operated educational appliances with visual presentation of the material to be studied, e.g. using film strip
• G06T 7/521 - Depth or shape recovery from the projection of structured light
• G06T 7/10 - Segmentation; Edge detection

Abstract

in vitroin vitro methods for detecting Delta-like 1 (DLL1) protein using an anti-DLL1 capture antibody and a labeled anti-DLL1 detection antibody. According to the invention, these antibodies can be used in an in vitro method to diagnose a severe infection, in particular a sepsis.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

The present invention relates to methods for assessing subjects presenting with suspected acute coronary syndrome. Specifically, the present invention relates to methods for classifying a patient with suspected acute coronary syndrome. The methods of the present invention may be carried out as computer-implemented methods.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

The present invention relates to a perivascular implant comprising (i) a housing comprising a receptacle for an effector matrix, and (ii) a fastening element adapted for at least partially embracing a tubular bodily structure, wherein said housing, said receptacle for an effector matrix, and said fastening element are arranged such that after implantation of the device the receptacle for an effector matrix at least partially is in contact with said tubular bodily structure and/or a vasculature originating from said tubular bodily structure, and to uses, methods, and kit related thereto.

IPC Classes  ?

• A61F 2/02 - Prostheses implantable into the body

Abstract

The present disclosure pertains to an in vitro method for the diagnostic classification of cancer based on the biological state of specific genomic sites. The disclosure provides a method that allows for a classification of a tumour sample obtained from a patient by analysing a multitude, preferably genome wide, collection of gene sites, combining the biological state of the analysed gene sites into a biological state pattern and comparing with pre-determined biological state patterns pertaining to different cancer types or tumour species. The disclosure is in particular useful for classifying cancer e.g. of the central nervous system, such as brain tumour samples and tumours of the spinal cord, since these are characterized by a large variety of distinct tumour species which have different prognostic values and require a developed treatment regime for each species in the clinical context. However, other cancers could similarly profit from the disclosure, for example sarcomas.

IPC Classes  ?

• G06N 20/20 - Ensemble learning
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 40/20 - Supervised data analysis
• G16B 40/30 - Unsupervised data analysis
• G06F 9/50 - Allocation of resources, e.g. of the central processing unit [CPU]
• G06F 15/78 - Architectures of general purpose stored program computers comprising a single central processing unit
• G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]
• G06N 3/02 - Neural networks

Abstract

The present disclosure relates to a computer-implemented method for cancer diagnosis, comprising: a) selectively sequencing polymers of a biological sample according to at least one target gene site by translocating the polymers through nanopores of a nanopore sequencing system, including: (i) analyzing an initial nucleotide sequence of a first polymer of the biological sample while the first polymer is translocating through a nanopore of the nanopore sequencing system to determine whether the initial nucleotide sequence corresponds to the at least one target gene site; and (ii) continuing the sequencing of the first polymer to obtain measurement data of the first polymer only if the initial nucleotide sequence of the first polymer corresponds to the at least one target gene site; b) determining, based on the measurement data, a biological state of a nucleotide sequence of the first polymer corresponding to the at least one target gene site; and c) classifying a cancer using a classification algorithm based on the biological state of the nucleotide sequence of the first polymer, wherein the classification algorithm is trained based on the at least one target gene site and biological state data pertaining to cancer types.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• G16B 40/20 - Supervised data analysis

Abstract

The present disclosure pertains to an in vitro method for the diagnostic classification of cancer based on the biological state of specific genomic sites. The disclosure provides a method that allows for a classification of a tumour sample obtained from a patient by analysing a multitude, preferably genome wide, collection of gene sites, combining the biological state of the analysed gene sites into a biological state pattern and comparing with pre-determined biological state patterns pertaining to different cancer types or tumour species. The disclosure is in particular useful for classifying cancer e.g. of the central nervous system, such as brain tumour samples and tumours of the spinal cord, since these are characterized by a large variety of distinct tumour species which have different prognostic values and require a developed treatment regime for each species in the clinical context. However, other cancers could similarly profit from the disclosure, for example sarcomas.

IPC Classes  ?

• G06N 20/20 - Ensemble learning
• G16B 40/20 - Supervised data analysis
• G16B 40/30 - Unsupervised data analysis
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G06F 9/50 - Allocation of resources, e.g. of the central processing unit [CPU]
• G06F 15/78 - Architectures of general purpose stored program computers comprising a single central processing unit
• G06N 3/02 - Neural networks
• G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]

Abstract

The present disclosure relates to a computer-implemented method for cancer diagnosis, comprising: a) selectively sequencing polymers of a biological sample according to at least one target gene site by translocating the polymers through nanopores of a nanopore sequencing system, including: (i) analyzing an initial nucleotide sequence of a first polymer of the biological sample while the first polymer is translocating through a nanopore of the nanopore sequencing system to determine whether the initial nucleotide sequence corresponds to the at least one target gene site; and (ii) continuing the sequencing of the first polymer to obtain measurement data of the first polymer only if the initial nucleotide sequence of the first polymer corresponds to the at least one target gene site; b) determining, based on the measurement data, a biological state of a nucleotide sequence of the first polymer corresponding to the at least one target gene site; and c) classifying a cancer using a classification algorithm based on the biological state of the nucleotide sequence of the first polymer, wherein the classification algorithm is trained based on the at least one target gene site and biological state data pertaining to cancer types.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• G16B 40/20 - Supervised data analysis

Abstract

The present invention relates to an endograft device (101) for treatment of ruptures (104.9) in one or more inner layers of a blood vessel (104), in particular, an aorta, comprising an anchoring unit (101.1) and a sleeve unit (101.2). The endograft device (101) defines an upstream endograft end (101.3) and a downstream endograft end (101.4), upstream and downstream being defined, in an implanted state of the endograft device (101), in relation to a general natural blood flow defining a blood flow direction within the blood vessel (104). The anchoring unit (101.1) is a collapsible unit located at the upstream endograft end (101.3), wherein the anchoring unit (101.1) is configured to anchor, in the implanted state, the endograft device (101) within the blood vessel (104) by engaging an inner surface of the blood vessel (104) with an expanded anchoring section (101.5). The sleeve unit (101.2) is located downstream of the anchoring unit (101.1), wherein the sleeve unit (101.2) is a thin- walled foldable element defining a longitudinal direction, a radial direction, a circumferential direction, an upstream sleeve unit end (101.7) and a upstream sleeve unit end (101.8). The sleeve unit (101.2) comprises an unsupported section (101.9) located at the upstream sleeve unit end (101.7), wherein the unsupported section (101.9) extends along the longitudinal direction and, at least in the implanted state, is unsupported over its entire circumference. The sleeve unit (101.2) is configured to be expanded, in the implanted state, to rest against an inner wall of the blood vessel (104) to sealingly cover the rupture (104.9) with the unsupported section (101.9).

IPC Classes  ?

• A61F 2/954 - Instruments specially adapted for placement or removal of stents or stent-grafts for placing stents or stent-grafts in a bifurcation
• A61F 2/07 - Stent-grafts
• A61F 2/848 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs

Abstract

The present invention relates to a method for identifying a subject susceptible to treatment of cancer by administration of a methylene quinuclidinone agent, said method comprising (a) determining in a sample of said subject at least four biomarkers independently selected from the group consisting of SLC7A11, PLS3, RHBDF1, CLDN1, FAM114A1, YAP1, TJP1, SEPTIN10; CORO1A, RHOH, CXCR4, PUM2, TRAF3IP3, KDM2B, ARHGAP9, IKZF1, ACAP1, and PDE7A; (b) comparing the result determined in step (a) to at least one reference, and (c), based on the result of step (b), identifying a subject susceptible to treatment of cancer by administration of a methylene quinuclidinone agent, and to compounds for use, kits, and devices related thereto.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

The present invention relates to a method for attaching a 5'-nicotinamidnucleobasedinucleotide (NND)- capped nucleic acid sequence to a fusion protein or to a complex, comprising (a) contacting (i) a heterologous fusion protein which comprises a poly(peptide) of interest being fused to a tag, or (ii) a complex wherein a protein is under physiological conditions complexed with a tag with the 5'-NAD- capped nucleic acid sequence and an ADP-ribosyltransferase (ART) under conditions wherein the 5'- NND-capped nucleic acid sequence is covalently attached to the tag, wherein the tag comprises a recognition motif of the ART and preferably comprises or consists of (i) SEQ ID NO: 1 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (ii) SEQ ID NO: 2 ora sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (iii) SEQ ID NO: 3 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif DVRPVRD (SEQ ID NO: 7) is conserved and preferably SEQ ID NO: 7 is conserved; (iv) SEQ ID NO: 4 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved; (v) SEQ ID NO: 5 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved; or (vi) SEQ ID NO: 6 or a sequence being at least 80% identical thereto provided that the underlined Arg in the amino acid motif LADGVEGYLRASEASRDRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
• C07K 19/00 - Hybrid peptides
• C12N 9/10 - Transferases (2.)
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

RRRRRRRVE (SEQ ID NO: 8) is conserved and preferably SEQ ID NO: 8 is conserved.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase

Abstract

The invention relates to a three-dimensional model for simulating medical, in particular dental, treatments, comprising at least one holding element for receiving artificial teeth and at least one artificial tooth, with the artificial tooth comprising at least one artificial tooth root and the artificial tooth root being at least partially held in a recess in the holding element. The object of providing a three-dimensional model with which realistic experience in the performance of both routine and complex dental and surgical interventions can be obtained inexpensively is achieved by a multiplicity of connecting strands being formed between the holding element and the artificial tooth, in particular the artificial tooth root. The invention also relates to a method for producing a three-dimensional model for simulating medical, in particular dental, treatments, in particular the three-dimensional model according to the invention, comprising at least one holding element for receiving artificial teeth and at least one artificial tooth, with the artificial tooth comprising at least one artificial tooth root and the artificial tooth root being at least partially held in a recess in the holding element, and also relates to a three-dimensional model for simulating medical, in particular dental, treatments, comprising at least one holding element, in particular for receiving artificial teeth, and an artificial nerve system comprising at least one artificial nerve, with the artificial nerve running at least partially through the holding means.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G09B 23/34 - Anatomical models with removable parts

Abstract

ulcerative colitis.ulcerative colitis.

IPC Classes  ?

• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61K 9/51 - Nanocapsules
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to xenon gas for use in vivo methods of sensitizing glioma cells in a subject for radiation therapy, as well as related in vitro methods.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

The present invention relates to diagnosis and treatment of malignancies characterised by prostate-specific membrane antigen (PSMA) expression. The invention particularly relates to improved radiopharmaceuticals which selectively bind to PSMA and are suitable for planar imaging of PSMA expression in subjects to diagnose and/or monitor malignancies wherein PSMA is (over)expressed. Additionally, the invention relates to improved radiopharmaceuticals which selectively bind to PSMA and are suitable to act as radionuclide treatment agents. The radiopharmaceuticals rely on a pharmacophore capable of interacting with PSMA and N-terminal mercaptoacetyltripeptides capable of coordinating radioactive metals such as technetium and rhenium.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07F 13/00 - Compounds containing elements of Groups 7 or 17 of the Periodic System
• A61K 51/04 - Organic compounds
• A61P 35/00 - Antineoplastic agents
• C07C 275/16 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups

Abstract

The present invention relates to artificial Antigen Presenting Cells (aAPCs) comprising artificial Antigen Presenting Molecules (aAPMs) and, in particular, comprising dimers of the aAPMs as well as to methods for producing aAPCs. The invention further relates to compositions comprising the aAPCs and to vectors encoding the aAPMs of the aAPCs. Embodiments of the invention have been particularly developed for use in assays for determining an antigen-specific T cell response or a plurality of antigen-specific T cell responses and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

The present invention relates to an inhibitor of mitoferrin-2 for use in treating a cancer with reduced activity of mitoferrin-1 in a subject. The present invention also relates to a method for identifying an inhibitor of mitoferrin-2 comprising (a) contacting a (i) host cell with a reduced mitoferrin-1 activity and (ii) a host cell with a non-reduced mitoferrin-1 activity with a candidate inhibitor of mitoferrin-2, (b) determining growth and/or morphology of the host cells of step (a); (c) identifying an inhibitor of mitoferrin-2 if a growth arrest and/or abnormal morphology is/are detected in step (b) in the host cell having the reduced activity of mitoferrin- 1 but not in the host cell with the non-reduced activity of mitoferrin-1. The present invention further relates to a method for identifying a subject susceptible to cancer treatment by an inhibitor of mitoferrin-2, comprising (A) determining mitoferrin-1 activity in a sample of said subject, preferably a sample of cancer cells, and (B) identifying a patient susceptible to cancer treatment by an inhibitor of mitoferrin-2 based on determining step (A).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

The invention relates to a method for producing an osteotropic bone replacement material from a starting material which substantially has portlandite, calcium oxide, aragonite; calcite and/or apatite. The starting material is introduced into an autoclave with a strontium, fluorine and/or gallium source, wherein when using a starting material which substantially has portlandite, calcium oxide, aragonite; calcite a phosphate source is introduced. In addition, H2O is added into the autoclave as part of a solvent and the pH value in the autoclave is set to a range above 7. Afterwards, the closed and filled autoclave is heated for at least 1 hour and then cooled. The osteotropic bone replacement material thus developed is subsequently cleaned from residues of the phosphorus, strontium, fluorine and/or gallium source. Furthermore, the invention relates to an osteotropic bone replacement material which substantially consists of apatite and in which strontium ions are incorporated into the crystal lattice.

IPC Classes  ?

• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• C04B 35/447 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on phosphates

Abstract

An underactuated mechanism has a first rotoidal joint connected to a human torso and rotating about a first joint rotation axis, a hyper-redundant connection mechanism connected to the first rotoidal joint, and a second rotoidal joint rotating about a second joint rotation axis, coplanar with the first joint rotation axis. The second rotoidal joint is remotely actuated by a driven pulley and Bowden cables or by a direct drive actuation system with co-located motor, and is fixed to the hyper-redundant connection mechanism on one side and to a human arm on the other side. The hyper-redundant connection mechanism has at least three members. Two members of the at least three members are rigidly fixed to one of the rotoidal joints, respectively. All members are connected together by rotation joints with axes parallel to one another and arranged to connect one member to a successive member to form a rotation constraint.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

The present disclosure provides variant AAV8 capsids that exhibit altered capsid properties, e.g., improved transduction efficiency and/or specificity for the liver. The present disclosure further provides nucleic acids encoding the variant AAV8 capsids, recombinant AAV (rAAV) vectors comprising the variant AAV8 capsids, as well as host cells and compositions comprising the same. The present disclosure further provides methods of delivering a gene product to a subject and methods of treatment of a liver-borne blood disorder, the methods generally involving administering an effective amount of the rAAV vectors to a subject in need thereof.

IPC Classes  ?

• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/864 - Parvoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

e.g.e.g., enhanced immune-escaping capacity. Also provided are nucleic acids encoding the variant AAV8 capsid polypeptides, recombinant AAV (rAAV) vectors comprising the variant AAV8 capsid polypeptides, as well as host cells and pharmaceutical compositions comprising the same. Further provided are methods of delivering a gene product to a subject and methods of treatment of a liver-borne blood disorder, the methods generally involving administering an effective amount of the rAAV vectors to a subject in need thereof.

IPC Classes  ?

• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 15/33 - Genes encoding viral proteins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/864 - Parvoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Summarizing the invention, a device is provided. The device comprises a sample tube comprising an open end; a cap configured to close the open end of the sample tube, the cap comprising a through-hole; a rod comprising a cavity, the rod being connected to the cap such that the cavity is in communication with the through-hole; and a swab tip connected to the rod such that the swab tip is in communication with the cavity; wherein the rod and the swab tip are configured to be positioned within the sample tube when the open end of the sample tube is closed by the cap.

IPC Classes  ?

• A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• A61B 10/02 - Instruments for taking cell samples or for biopsy

Abstract

The present invention relates to means and methods for conjugating/attaching target molecules such as proteins to a label and/or carrier. Specifically, the present invention provides a complex comprising a metal cation coordinating (i) nitrate as a metal cation ligand and (ii) a metal cation chelating domain comprising a chelating ligand and a label and/or carrier. This complex can be used for attaching a label and/or a carrier to a target molecule, preferably a protein. The attachment of the label or carrier via the complex of the invention involves the replacement of the metal cation ligand with a coordinating group of the target molecule so that a product complex with the target molecule as primary ligand in the coordination sphere of the metal cation is formed. Accordingly, the present invention also provides for uses and methods involving the attachment of a label and/or carrier to a target molecule. Also provided are the products obtained by the labeling and or carrier-attaching methods of the invention and uses thereof. The invention further relates to methods for producing the complex of the invention and kits comprising the components for producing the complex of the invention.

IPC Classes  ?

• C07F 15/06 - Cobalt compounds
• C07K 1/13 - Labelling of peptides
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

The present invention relates to a polynucleotide encoding a nuclear polypeptide comprising a cargo polypeptide and an N-terminal activity-optimizing peptide (NAO peptide), wherein said NAO peptide comprises (i) a tag peptide, (ii) a linker peptide; and (iii) a nuclear localization sequence (NLS) peptide wherein said linker peptide comprises at least three small amino acids independently selected from glycine, alanine, leucine, serine, aspartate, asparagine, threonine, phenylalanine, glutamate, glutamine, histidine, arginine, lysine, valine, isoleucine, and proline, more preferably from glycine, alanine, proline, serine, valine, and threonine; and wherein said tag peptide is fused at its C-terminus to the linker peptide; and to vectors, polypeptides, host cells, and methods related thereto.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention relates to a method of identifying a T-cell reactive to cells presenting a T-cell activating antigen (cancer-reactive T-cell), comprising (a) determining expression of at least one of CCL4, CCL4L2, CCL3, CCL3L1, and CXCL13 in T-cells from a sample of a subject; and (b) identifying a cancer-reactive T-cell based on the determination of step (a). The present invention also relates to a method of identifying a TCR binding to a cancer cell of a subject, said method comprising (A) identifying a cancer reactive T-cell according to the afore-said method (B) providing the amino acid sequences of at least the complementarity determining regions (CDRs) of the TCR of the cancer-reactive T-cell identified in step (A); and, hereby, (C) identifying a TCR binding to a cancer cell. The present invention further relates to further methods and cancer-reactive T-cells related thereto.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to a method of identifying a T-cell reactive to cells presenting a T-cell activating antigen (cancer-reactive T-cell), comprising (a) determining expression of at least one of CCL4, CCL4L2, CCL3, CCL3L1, and CXCL13 in T-cells from a sample of a subject; and (b) identifying a cancer-reactive T-cell based on the determination of step (a). The present invention also relates to a method of identifying a TCR binding to a cancer cell of a subject, said method comprising (A) identifying a cancer reactive T-cell according to the afore-said method (B) providing the amino acid sequences of at least the complementarity determining regions (CDRs) of the TCR of the cancer-reactive T-cell identified in step (A); and, hereby, (C) identifying a TCR binding to a cancer cell. The present invention further relates to further methods and cancer-reactive T-cells related thereto.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to a method of identifying a T-cell reactive to cells presenting a T-cell activating antigen (cancer-reactive T-cell), comprising (a) determining expression of at least one of CCL4, CCL4L2, CCL3, CCL3L1, and CXCL13 in T-cells from a sample of a subject; and (b) identifying a cancer-reactive T-cell based on the determination of step (a). The present invention also relates to a method of identifying a TCR binding to a cancer cell of a subject, said method comprising (A) identifying a cancer reactive T-cell according to the afore-said method (B) providing the amino acid sequences of at least the complementarity determining regions (CDRs) of the TCR of the cancer-reactive T-cell identified in step (A); and, hereby, (C) identifying a TCR binding to a cancer cell. The present invention further relates to further methods and cancer-reactive T-cells related thereto.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide, or a therapeutically active variant thereof, for use in the treatment of cancer in a subject. Moreover, the present invention provides an agent which increases the amount of an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide for use in treating cancer. Further, encompassed by the present invention is a method for identifying a candidate compound for the treatment of cancer.

IPC Classes  ?

• A61K 38/18 - Growth factors; Growth regulators
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

A force measuring plate having a planar regular arrangement of force measuring cells. A force measuring cell is formed in a hole in the force measuring plate, in which hole precisely one planar element which is secured by springs in a self-supporting fashion is arranged and is oriented so as to run parallel to the force measuring plate. Each spring is connected in a materially joined fashion at a first end to the edge of a hole and at a second end to the edge of a planar element. The force measuring plate, the springs and the planar elements are formed from the same material. Each planar element can be elastically deflected in three spatial directions under the effect of a force. There is a linear relationship between the deflection and the force. In addition, the invention relates to a device for determining forces in the piconewton to nanonewton ranges.

IPC Classes  ?

• G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention relates to an apparatus for analyzing single tumor cells, said apparatus comprising a hydrogel-based polymeric microcapsule for entrapping cells and a hydrogel having on its surface a single cell migration path being formed by one or more extracellular matrix proteins and/or one or more polymers comprising RGD peptides or proteins, wherein the polymeric microcapsule and the path are placed in the apparatus such that upon the release of cells from the polymeric microcapsule a single tumor cell can migrate from the polymeric microcapsule on the path.

IPC Classes  ?

• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

The present invention relates to a method for predicting the risk of mortality of a subject suffering from cancer. The method comprises the steps of a) determining the amount of nANGPTL-4 (N-terminal fragment of angiopoietin like 4) in a first serum, plasma or blood sample from the subject, b) determining the amount of nANGPTL-4 (N-terminal fragment of an angiopoietin like 4) in a second serum, plasma or blood sample from the subject, wherein said second serum, plasma or blood sample has been obtained after said first sample, c) comparing the amount of nANGPTL-4 in the second blood, serum or plasma sample to the amount in the first blood, serum or plasma sample, and d) predicting the risk of mortality of the subject based on the results of step c).

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The present invention relates to compounds that inhibit expression of Id1 and/or Id3, as well as uses thereof in the treatment of cancer and other diseases and conditions associated with Id1 and/or Id3 expression.

IPC Classes  ?

• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to a compound of general formula (I) in which X is selected from consisting of a first group, a second group or a third group, wherein the first group consists of and, the second group consists of and, and the third group consists of and; Y is a group of general formula II or of general formula (III) if X is selected from the first group, Z is selected from a first group consisting of if X is selected from the second group, Z is selected from a second group consisting of and; if X is selected from the third group, Z is selected from a third group consisting of and, R1and R21616 6 heteroalkyl group, -C(O)-O-Ra, -C(O)-NRbRc, -C(O)-C(Ra)2-NRbRc, and -C(O)-NRb22)n-C(O)- O-Ra, wherein Ra, Rband Rc166 heteroalkyl group, a substituted or unsubstituted aryl group and a group L and n is an integer from 1 to 10; R3is selected from the group consisting of oxygen, sulfur, =NRd, and =CHRd, wherein Rd16166 heteroalkyl group, a substituted or unsubstituted aryl group, -O-Re, -C(O)-O-Re, -C(O)-NRfRg166 alkyl group, and Rf and Rg166 alkyl group; and R4 is selected from the group consisting of -ORh, -SRh, -NHRh22Rh1616161622mm-NRmRn, a group -A-L and a group L, Rk16166 heteroalkyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted carboxy group, Rmand Rn166 alkyl group, and m is 0 or an integer from 1 to 10; R5and R6independently are selected from the group consisting of hydrogen, chloro, bromo, iodo, and O-Ro, wherein Ro166 alkyl group; A is a linker group and L is an amino acid residue or a peptide.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61K 103/40 - Actinides
• C07D 471/08 - Bridged systems

Abstract

The present invention relates to a core-shell particle comprising a core cross-linked polymeric micelle (CCPM), and one or more iron oxide nanoparticles (IONs), wherein the one or more ION is located in the core of the CCPM. Further provided are methods for producing the core-shell particle, compositions comprising the same, the core-shell particle or the composition for use in medicine, and methods for modulating the activity of immune cells and methods of treating dysregulation of the immune system, cancer, anemia and nerve injuries.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 33/26 - Iron; Compounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method of classifying a sample of a patient that suffers from or being at risk of developing urothelial or bladder cancer, said method comprising the steps of: a) determining in said sample from said patient, the presence or absence of alteration in an FGFR gene and/or the expression level of at least one gene encoding for a receptor selected from the group consisting of FGFR1, FGFR2, FGFR3 or FGFR4, and b) classifying the sample of said patient from the outcome of step a) into one of at least two classifications, said classifications comprising good and poor prognosis for treatment with an anti-cancer agent.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present invention relates to a method for diagnosing or prognosing cancer comprising determining in vitro cytosine methylation levels within marker genes and/or determining expression levels of miRNA markers.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to pharmaceutical compositions with isolated and treated whole blood cells or Peripheral Blood Mononuclear Cells (PBMCs) as well as such pharmaceutical compositions for use in the prevention and/or treatment of organ or cell graft rejection in a human graft recipient.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/405 - Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Abstract

The present invention relates to a compound decreasing the concentration of 2-hydroxy-glutarate (2HG) in a subject for use in treating, preventing, and/or preventing progression of cardiac remodeling, in particular cardiomyopathy and/or heart failure and to viral particles, compositions, uses and methods related thereto.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 9/51 - Nanocapsules
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

The invention relates to oral pharmaceutical compositions of an active agent and a lipid conjugate of a cell penetrating peptide conjugated to a lipid molecule. The conjugated lipid acts as a permeation enhancer for the active agent in the composition. In other words, oral bioavailability of the active agent increases when co-administered together with the lipid conjugate described herein.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 9/51 - Nanocapsules
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 38/26 - Glucagons
• A61K 38/31 - Somatostatins

Abstract

The present invention relates to a polynucleotide comprising an expressible nucleic acid sequence encoding a relaxin family peptide receptor (RXFP) polypeptide for use in treatment and/or prevention of heart failure in a subject. The present invention further relates to a vector comprising the polynucleotide of the present invention for use in treatment and/or prevention of heart failure, as well as to host cells, RXFP agonists, kits and devices related thereto.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 35/76 - Viruses; Subviral particles; Bacteriophages
• A61K 38/22 - Hormones
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

The present invention relates to a method of making an oral dosage form comprising the steps of reacting at least one cell penetrating peptide (CPP), purifying CPP-lipid conjugates, processing a lipid batch to obtain CPP-modified liposomes and incorporating a liposome lyophilisate into an oral dosage form. The present invention further relates to oral dosage forms and oral dosage forms for use in a therapeutic method.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a compound of formula (1) (I), wherein Y3 is O or S, wherein s, t, u and w are 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2 and Z3 are selected from the group consisting of CO2H, —SO2H, —SO3H, —OSO3H, and -0P03H2, R1 is —CH3 or H, X is selected from the group consisting of alkylaryl, aryl, alkylheteroaryl and heteroaryl, Y1 and Y2 are selected from the group consisting of aryl, alkylaryl, cycloalkyl, heterocycloalkyl, heteroaryl and alkylheteroaryl, and wherein A is a chelator residue having a structure selected from the group consisting of (la), (lb) and (lc), wherein R2, R3, R4 and R5 are selected from the group consisting of H, —CH2—COOH and —CH2—C(=0)-NH2 or wherein R2 and R4 form a —(CH2)n— bridge with n being an integer of from 1 to 3, wherein n is preferably 2, and wherein r, v and q are 0 or 1, with the proviso that in case u and w are 0, q and v are 0, and (A) wherein u and w are 1, or (B) wherein u is 0 and w is 1, and wherein A is selected from (la) or (lb), or (C) wherein A is not The compound is disclosed for use in the treatment of PSMA-expressing cancer. The present invention relates to a compound of formula (1) (I), wherein Y3 is O or S, wherein s, t, u and w are 0 or 1, wherein i is an integer of from 1 to 3, wherein j is an integer of from 3 to 5, and wherein Z1, Z2 and Z3 are selected from the group consisting of CO2H, —SO2H, —SO3H, —OSO3H, and -0P03H2, R1 is —CH3 or H, X is selected from the group consisting of alkylaryl, aryl, alkylheteroaryl and heteroaryl, Y1 and Y2 are selected from the group consisting of aryl, alkylaryl, cycloalkyl, heterocycloalkyl, heteroaryl and alkylheteroaryl, and wherein A is a chelator residue having a structure selected from the group consisting of (la), (lb) and (lc), wherein R2, R3, R4 and R5 are selected from the group consisting of H, —CH2—COOH and —CH2—C(=0)-NH2 or wherein R2 and R4 form a —(CH2)n— bridge with n being an integer of from 1 to 3, wherein n is preferably 2, and wherein r, v and q are 0 or 1, with the proviso that in case u and w are 0, q and v are 0, and (A) wherein u and w are 1, or (B) wherein u is 0 and w is 1, and wherein A is selected from (la) or (lb), or (C) wherein A is not The compound is disclosed for use in the treatment of PSMA-expressing cancer.

IPC Classes  ?

• A61K 51/04 - Organic compounds

Abstract

The present invention relates to cobicistat and its derivatives or prodrugs for use in the prophylaxis and/or treatment of severe acute respiratory syndrome coronavirus type 2 (SARS- CoV-2) infection, severe acute respiratory syndrome coronavirus (SARS-CoV) infection and/or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. The present invention further relates to methods of prevention and/or treatment of SARS-CoV-2 infection.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/4433 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 38/05 - Dipeptides
• A61P 31/14 - Antivirals for RNA viruses
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Described herein is an adeno-associated virus (AAV) capsid polypeptide bonded to a binding peptide including an amino acid sequence RGDX1X2X3X4, with X1 to X4 being independently selected amino acids, for use in treating and/or preventing a muscular disease and/or in muscle regeneration. Also described are polynucleotides, host cells, adeno-associated virus (AAV) capsids, pharmaceutical compositions, uses, and methods related to the AAV capsid polypeptide.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Abstract

The present invention relates to a compound, a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical composition for use in the in vivo diagnosis or treatment of ischemia.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 103/00 - Radioactive metals

Abstract

The present invention provides method of studying an effect of a test substance on a test sample of bio-logical cells using a set of relevant parameters and a set of meta-features, the method comprising: exposing the test sample to the test substance; determining parameter values of the set of relevant parameters for each of a plurality of cells in the test sample; and determining feature values of the set of meta-features for the test sample, wherein each of the feature values is calculated from the parameter values of a cluster of correlated parameters from the set of relevant parameters that is associated with the respective meta-feature, wherein a reference sample for determining the set of meta-features was exposed to a stimulus substance.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

The invention relates to the use of a recombinant porcine adeno-associated virus (AAV) vector comprising a peptide-modified porcine AAV serotype 1 (AAVpo1) capsid in gene therapy of muscle and/or central nervous system (CNS) disorders, in particular neuromuscular diseases such as genetic neuromuscular diseases.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

The invention relates to the use of a recombinant porcine adeno-associated virus (AAV) vector comprising a peptide-modified porcine AAV serotype 1 (AAVpo1) capsid in gene therapy of muscle and/or central nervous system (CNS) disorders, in particular neuromuscular diseases such as genetic neuromuscular diseases.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 15/86 - Viral vectors
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a method for preparing a compound T having a thioether group from a compound D having a disulfide group in the presence of a carbene.

IPC Classes  ?

• C07C 319/14 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
• C07C 321/20 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
• C07C 323/16 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• C07C 323/07 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and halogen atoms, or nitro or nitroso groups bound to the same carbon skeleton having sulfur atoms of thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• C07C 323/56 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• C07C 323/59 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
• C07D 307/38 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms

Abstract

The disclosure in particular relates to a ventricular assist device for implantation into a lumen of a blood vessel, comprising an impeller fixed to a rotor shaft, wherein the impeller is configured to rotate around a longitudinal axis of the rotor shaft; a drive unit comprising a magnetic motor configured to cause rotation of the impeller around to the longitudinal axis; a first active magnetic bearing configured to bear a first end section of the rotor shaft relative to the drive unit; a second active magnetic bearing configured to bear a second end section of the rotor shaft relative to the drive unit; and a control unit configured to control the magnetic motor, the first active magnetic bearing and the second active magnetic bearing.

IPC Classes  ?

• A61M 60/822 - Magnetic bearings specially adapted for being actively controlled
• A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
• A61M 60/237 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller the blood flow through the rotating member having mainly axial components, e.g. axial flow pumps
• A61M 60/422 - Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being electromagnetic, e.g. using canned motor pumps
• A61M 60/861 - Connections or anchorings for connecting or anchoring pumps or pumping devices to parts of the patient’s body

Abstract

The present invention relates to compositions, methods, and devices for preventing irregular electromechanical waves in the myocardium that lead to pathological conditions as arrhythmia. In particular, the invention relates to compositions and methods to increase the conductivity of the myocardium to restore an impairment of the electrical conduction system of the heart. To that end substances with high conductivity, as carbon nanotube suspensions or metal nanowire suspensions, are injected in the myocardium at closely adjacent locations on circular or open lines or are introduced in patches of cardiomyocytes that are subsequently placed on the myocardium.

IPC Classes  ?

• A61L 27/08 - Carbon
• A61L 27/04 - Metals or alloys
• A61L 27/38 - Animal cells

Abstract

222-; Z is N or C, preferably is N; m is an integer of from 0 to 3, preferably is 0; n is an integer of from 1 to 3, preferably is 1; R156 6 cycloalkyl or aryl; R2is, optionally substituted, aryl or heteroaryl; R3and R4are -H, or R3and R4222- bridge; R5and R7are independently selected from alkyl, preferably methyl and isopropyl; and in case Z is N, R6is absent, or, in case Z is C, R6together with R5 forms a -CH=CH-CH=CH- bridge; and/or (ii) a C-C chemokine receptor type 5 (CCR5) inhibitor, for use in treating and/or preventing pneumonia, sepsis, and/or coronavirus infection in a subject, and to methods, uses, kits an devices related thereto.

IPC Classes  ?

• A61K 31/46 - 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• A61P 31/12 - Antivirals
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
• A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 38/19 - Cytokines; Lymphokines; Interferons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof, The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof, The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II) The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II) The present invention relates to a compound having a structure as shown in formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein R1 is ethyl, —H, or methyl and R2 is a side chain having a structure as shown in formula (II) wherein X1 is C═O, CH2, C═S, C—OH, C—NH2, or C—NO2, X2 to X4 are independently selected from CH2, C═O, C═S, C—OH, and C—NH2, or R2 is —NH2, for use in treating and/or preventing of atrial arrhythmia in a subject. The present invention further relates to pharmaceutical compositions and kit related to said compound.

IPC Classes  ?

• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 9/06 - Antiarrhythmics

Abstract

The present invention relates to compounds that inhibit the activity of flavivirus.

IPC Classes  ?

• C07C 233/02 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61P 31/12 - Antivirals
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Abstract

The present invention relates to compounds that inhibit the activity of flavivirus.

IPC Classes  ?

• C07C 233/02 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• A61P 31/12 - Antivirals
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Abstract

The present disclosure provides a computer implemented method for facilitating a teaching surgeon to teach or assist a learning surgeon in minimally invasive interventions using a surgical instrument, said method comprising the following steps: displaying endoscopic images of an intervention site in real time on a display device, said endoscopic images being captured using a camera associated with an endoscopic instrument, tracking a movement of one or both hands of said teaching surgeon and/or a device held by said teaching surgeon, using a real-time tracking apparatus, wherein said real-time tracking apparatus comprises a tracking system and a computing device, wherein said tracking of said movement comprises the steps of recording a sequence of tracking information of one or both hands of said teaching surgeon and/or the device held by said teaching surgeon, said sequence of tracking information including real-time information regarding a movement of said one or both hands of the teaching surgeon and/or said device held by said teaching surgeon, and receiving, by said computing device or module, said recorded sequence of tracking information and extracting said real-time information regarding said movement of the one or both hands or the device from said recorded sequence of tracking information, and overlaying a visual representation of the tracked movement of said one or both hands or said device over the real-time endoscopic image, thereby allowing the teaching surgeon to carry out gestures with one or both hands which are displayed on the endoscopic image and allow for teaching or instructing the learning surgeon.

IPC Classes  ?

• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G09B 9/00 - Simulators for teaching or training purposes
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine

Abstract

The present invention relates to a polypeptide and a nucleic acid encoding the polypeptide for use in a method of detecting the presence of hepatitis D virus (HDV) and/or of diagnosing an HDV infection and/or of monitoring the treatment of an HDV infection. The present invention further relates to an in vitro method, an immunographic test device as well as a kit. In particular, the present invention relates to a point of care diagnostic for HDV infections.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C07K 14/08 - RNA viruses
• C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
• A61K 39/29 - Hepatitis virus
• G01N 33/576 - Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

Abstract

Summary The present invention relates to a method for the selective amplification or modification of DNA or RNA in a sample containing a mixture of RNA and DNA. Also, the present invention relates to the use of this method in detection, sequencing, DNA immunoprecipitation (DIP), methylation analysis, RNA immunoprecipitation (RIP), selective labelling of DNA or RNA molecules and massive parallel sequencing.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present invention relates to a bioactive compound delivery assembly, a method for stabilization and/or encapsulation of bioactive compound compositions, a method for solid-supported transfection of living cells as well as a use of the bioactive compound delivery assembly.

IPC Classes  ?

• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention relates to a polynucleotide encoding a fusion polypeptide comprising an anti-CRISPR (Acr) polypeptide, wherein said fusion polypeptide further comprises a receptor domain changing conformation upon reception of a stimulus. The present invention also relates to a vector comprising the polynucleotide of the present invention, to a bipartite Acr polypeptide comprising a first partial Acr polypeptide comprising amino acids corresponding to amino acids 10 to 62 of SEQ ID NO: 1, and a second partial Acr polypeptide comprising amino acids corresponding to amino acids 67 to 77 of SEQ ID NO: 1, and to a host cell comprising the aforesaid polynucleotide compounds. The present invention also relates to the said compounds for use in medicine, in particular for use in treatment and/or prevention of genetic disease, neurodegenerative disease, cancer, and/or infectious disease. Moreover, the present invention also relates to a kit, methods, and uses related thereto.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to an NF-κB inhibitor or a pharmaceutically acceptable salt or prodrug thereof for use in treating lymphoma, wherein said use further comprises administration of at least one agent activating the intrinsic pathway of apoptosis; and to an agent activating the intrinsic pathway of apoptosis or a pharmaceutically acceptable salt or prodrug thereof for use in treating lymphoma, wherein said use further comprises administration of at least one NF-κB inhibitor. The present invention further relates to combined preparations, medicaments, kits, and methods related thereto.

IPC Classes  ?

• A61K 31/225 - Polycarboxylic acids
• A61P 35/00 - Antineoplastic agents
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

A body fluid leakage detection aqueous composition, for use e.g. in intraoperative pancreatic fluid leakage detection. The composition comprises a gelling agent, increasing the viscosity of the composition, and buffering species, the composition thereby being buffered. The gelling agent is cross-linked α-glucan microspheres. Further, the composition comprises a pH-indicator. The pH of the composition is at least 0.1 pH units lower, or higher, than a pKa of the pH-indicator.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
• A61B 17/06 - Needles; Holders or packages for needles or suture materials
• A61B 17/064 - Surgical staples
• A61K 49/00 - Preparations for testing in vivo

Abstract

2 can be defined manually or computed automatically from the image.

IPC Classes  ?

• G09G 5/02 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the way in which colour is displayed
• G06T 7/11 - Region-based segmentation
• G06T 7/90 - Determination of colour characteristics
• G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06K 9/62 - Methods or arrangements for recognition using electronic means
• G06T 7/00 - Image analysis
• G06T 11/00 - 2D [Two Dimensional] image generation
• G06V 10/56 - Extraction of image or video features relating to colour

Goods & Services

Carriers, other than for medical use, In particular Chemically treated test strips, other than for medical use. Carriers, For medical use, Especially, Medical diagnostic test strips; Diagnostic materials and diagnostic preparations for medical purposes; Chemical test reagents [medical]; Medical diagnostic reagents and assays for testing of body fluids. Laboratory apparatus, Laboratory equipment, Other than for medical purposes; Instruments for diagnosis [for scientific use]; Wafer sticks, For laboratory use, Other than for medical purposes, Especially, Mini test tubes for laboratory purposes for collecting swabs through carrier materials in the form of sticks; Databases, Especially, Electronic and interactive databases, all related to medical purposes, For laboratory use, All for use in research. Medical and veterinary apparatus and instruments; Diagnostic and examination apparatus; Testing apparatus for medical and/or veterinary purposes; Testing apparatus for medical purposes, veterinary testing apparatus; Equipment, Instruments, Relating to the following purposes, medical diagnosis, Veterinary diagnosis; Mini test tubes, formedical purposes, in particular, Relating to the following purposes, Collecting swabs and mini test tubes containing carrier materials in the form of sticks for collecting swabs. Laboratory services and Research laboratories, Especially Analytical laboratory services, Laboratory services for analytic testing, microbiological analyses and conducting microbiological testing; Laboratory services for analytical testing; Design and development of medical diagnostic apparatus; deployment, in relation to the following fields, Scientific and research information, Scientific research results, medical data, Especially, Examination results of medical testing via an online searchable database. Medical diagnostic services, Especially Microbiological analyses In the medical field; Laboratory analysis services relating to the treatment of persons.

Abstract

The present invention relates to artificial Antigen Presenting Cells (aAPCs) comprising artificial Antigen Presenting Molecules (aAPMs) and, in particular, comprising dimers of the aAPMs as well as to methods for producing aAPCs. The invention further relates to compositions comprising the aAPCs and to vectors encoding the aAPMs of the aAPCs. Embodiments of the invention have been particularly developed for use in assays for determining an antigen-specific T cell response or a plurality of antigen-specific T cell responses and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

A method for the identification of compounds modulating the biological activity of FGF2, the method comprising the use of target cells sensitive to the presence of FGF2 by obstructing proliferation, wherein the target cells constitutively express a first reporter in- the nucleus of living target cells.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present invention relates to conjugate compounds which comprise a peptide moiety (a) which is preferably a hydrophobic modified preS-derived peptide of hepatitis B virus or a respective cyclic peptide, and a NTCP substrate moiety (b), which is preferably a bile acid. The present invention further relates to pharmaceutical compositions comprising at least one conjugate compound. The present invention further relates to medical uses of said conjugate compounds and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a said diseases and/or infections.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present invention relates to conjugate compounds which comprise a peptide moiety (a) which is preferably a hydrophobic modified preS-derived peptide of hepatitis B virus or a respective cyclic peptide, and a NTCP substrate moiety (b), which is preferably a bile acid. The present invention further relates to pharmaceutical compositions comprising at least one conjugate compound. The present invention further relates to medical uses of said conjugate compounds and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a said diseases and/or infections.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/12 - Viral antigens
• A61K 39/29 - Hepatitis virus
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61P 31/20 - Antivirals for DNA viruses

Abstract

A computer-implemented method for testing ocular drug delivery is provided. The ocular drug delivery is characterized by a set of delivery parameters comprising at least one of drug type, drug concentration, drug amount, injection position, penetration depth. The method comprises: providing a model for the human eye, wherein the model comprises: a geometry equation defining a three-dimensional generalized limacon for the geometry of the vitreous body, geometry equations describing all components of the eye; and a set of equations defining a drug convection in the vitreous body; setting a target drug state in the vitreous body; using the model to perform at least one simulation of the ocular drug delivery with a given set of values for the set of delivery parameters, wherein the at least one simulation provides a simulated drug state in the vitreous body; comparing the target drug state and the simulated drug state.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• B33Y 80/00 - Products made by additive manufacturing
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine

Abstract

A light source device including a light emitting element for emitting a light having the following characteristics: a wavelength ranging from 435 to 520 nm, and a power density greater than 20 mW/cm2, the light source device provides an effective fluence to any contaminating and/or pathogenic agent greater than 11 J/cm2. Also, a light source assembly including a product adapted to be in contact with a support or a medium, preferably the skin or a wound and a light source device connected to the product for providing light to at least one contaminating and/or pathogenic agent present on a support or in a medium.

IPC Classes  ?

• A61L 2/26 - Accessories
• A61L 2/08 - Radiation
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
• A61L 9/18 - Radiation
• A61N 5/06 - Radiation therapy using light
• A23L 3/26 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by irradiation without heating
• C02F 1/30 - Treatment of water, waste water, or sewage by irradiation

Abstract

22O is added into the autoclave as part of a solvent, and the pH value in the autoclave is set to a range above 7. The closed and filled autoclave is then heated for at least one hour and then cooled. The osteotropic bone replacement material produced in this manner is then cleaned of phosphorus, strontium, fluorine, and/or gallium source residue. The invention also relates to an osteotropic bone replacement material which substantially consists of apatite and in which strontium ions are incorporated into the crystalline lattice.

IPC Classes  ?

• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• C01B 25/32 - Phosphates of magnesium, calcium, strontium, or barium

Abstract

The invention relates to a method for producing an osteotropic bone replacement material from a starting material which substantially has portlandite, calcium oxide, aragonite, calcite, and/or apatite. The starting material is introduced into an autoclave together with a strontium, fluorine, and/or gallium source. A phosphate source is introduced while using a starting material which substantially has portlandite, calcium oxide, aragonite, calcite, and/or apatite. Additionally, H2O is added into the autoclave as part of a solvent, and the pH value in the autoclave is set to a range above 7. The closed and filled autoclave is then heated for at least one hour and then cooled. The osteotropic bone replacement material produced in this manner is then cleaned of phosphorus, strontium, fluorine, and/or gallium source residue. The invention also relates to an osteotropic bone replacement material which substantially consists of apatite and in which strontium ions are incorporated into the crystalline lattice.

IPC Classes  ?

• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• C01B 25/32 - Phosphates of magnesium, calcium, strontium, or barium

Abstract

The present invention relates to an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide, or a therapeutically active variant thereof, for use in the treatment of cancer in a subject. Moreover, the present invention provides an agent which increases the amount of an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide for use in treating cancer. Further, encompassed by the present invention is a method for identifying a candidate compound for the treatment of cancer.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/515 - Angiogenic factor; Angiogenin
• A61K 38/18 - Growth factors; Growth regulators
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for modifying a target site in a host cell comprising contacting said host cell with a Cas nuclease, wherein said host cell is further contacted with a low-affinity Cas inhibitor and/or a sub-inhibitory concentration of a Cas inhibitor; and to a method for improving specificity of a Cas nuclease, comprising a) providing a Cas nuclease; and b) contacting said Cas nuclease with a low-affinity Cas inhibitor or a sub-inhibitory concentration of a Cas inhibitor; and c) thereby improving specificity of said Cas enzyme. Further, the present invention relates to compositions, polypeptides, uses and methods related thereto.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• A61K 38/46 - Hydrolases (3)
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present invention relates to compounds that inhibit expression of Id1 and/or Id3, as well as uses thereof in the treatment of cancer and other diseases and conditions associated with Id1 and/or Id3 expression.

IPC Classes  ?

• C07D 209/12 - Radicals substituted by oxygen atoms
• C07D 209/22 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
• C07D 209/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
• C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
• C07D 231/56 - Benzopyrazoles; Hydrogenated benzopyrazoles
• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61P 35/00 - Antineoplastic agents

Abstract

An underactuated mechanism (1), which allows the actuation of a distal degree of freedom of the shoulder joint and the transfer of the torques and the reaction force, generated by the actuation system on the frame (3) integral with the torso (5), through a hyper-redundant kinematic mechanism (200), is formed as follows: a. a first non -actuated rotoidal joint (100) connected to the human torso (5), which rotates about the axis X, b. a connection mechanism (200) connected to the first rotoidal joint (100), c. a second rotoidal joint (300) which (i) rotates about the axis Y arranged according to the degree of flexion-extension of the shoulder joint, which is coplanar with the axis X, (ii) is remotely actuated by a driven pulley and Bowden cables or by a direct drive actuation system with co-located motor, (iii) is fixed to the connection mechanism (200) on one side and to the human arm (6) on the other side, with the connection mechanism (200) consisting of: at least three or more members (210, 220, 231 ), two of which (210, 220) being rigidly fixed to one of the rotoidal joints (100, 300), respectively, all with parallel joints, referred to as minimum joints A and B, arranged so as to connect one member with the next one to form a rotation constraint about the axis of said parallel joints.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

The present invention relates to means and methods for conjugating/ attaching target molecules such as proteins to a label and/or carrier. Specifically, the present invention provides a complex comprising a metal cation coordinating (i) nitrate as a metal cation ligand and (ii) a metal cation chelating domain comprising a chelating ligand and a label and/or carrier. This complex can be used for attaching a label and/or a carrier to a target molecule, preferably a protein. The attachment of the label or carrier via the complex of the invention involves the replacement of the metal cation ligand with a coordinating group of the target molecule so that a product complex with the target molecule as primary ligand in the coordination sphere of the metal cation is formed. Accordingly, the present invention also provides for uses and methods involving the attachment of a label and/or carrier to a target molecule. Also provided are the products obtained by the labeling and or carrier-attaching methods of the invention and uses thereof. The invention further relates to methods for producing the complex of the invention and kits comprising the components for producing the complex of the invention.

IPC Classes  ?

• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07F 15/06 - Cobalt compounds
• C07K 1/13 - Labelling of peptides